Biotech Values

[vinmantoo]

ENTA reports additional post-hoc EDP-235 analyses_from_ phase-2_trial—details_in_new_corporate_slide_set:

Thanks so much Dew. A confirmed dose dependent viral decline for EDP-235 is very good news as it demonstrates EDP-235 anti-viral activity. That was expected given the dose dependent statistically significant improvement of symptoms, but it is good to see some hard data confirming it. Slides 27-33 relate to the SPRINT trial, with slide 31 being the one showing viral decline in the nucleocapsid Ab negative (vaccination only) population. It makes me more confident that a deal can/will be made for EDP-235 to run a phase 3 trial.